This is a randomized, open-label study of HLX10 plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: Arm A (HLX10): HLX10 + chemotherapy (carboplatin-etoposide) Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
1 Primary · 6 Secondary · Reporting Duration: approximately up to 24 months
Active Control
Experimental Treatment
200 Total Participants · 2 Treatment Groups
Primary Treatment: HLX10 + chemotherapy · No Placebo Group · Phase 3
Travel, including flights, are covered
Your expenses for travel tickets for this trial will be reimbursed.
Age 18 - No maximum age · All Participants · 13 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Washington | 100.0% |
65+ | 50.0% |
18 - 65 | 50.0% |
Research site | 100.0% |
Did not meet criteria | 100.0% |